

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Barbas III et al.**  
Serial No.: 09/586,625  
Filed: June 2, 2000  
For: **LIGAND ACTIVATED TRANSCRIPTIONAL  
REGULATOR PROTEINS**  
Art Unit: 1645  
Examiner: Unassigned

**RECEIVED**

**JAN 22 2001**

**TECH CENTER 1600/2900**

01 JAN 17 PM 2:55

RECEIVED  
TECH CENTER 1600/2900

#6  
BQ  
1/24/01

**INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE  
WITH 37 C.F.R. §§ 1.97-1.98**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§ 1.97-1.98. Forms PTO-1449 (7 pages) and copies of the cited documents are provided herewith in connection with the above-captioned application.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications, which are commonly owned and/or have one or more inventors in common.

**U.S.S.N.(App. no.)**  
P60/115,920

**Inventor**  
Von Seggern *et al.*

**Filing Date**  
01/14/99

**U.S.S.N. 09/586,625**  
**Barbas III et al.**  
**Information Disclosure Statement**

<u>U.S.S.N. (App. no.)</u>	<u>Inventor</u>	<u>Filing Date</u>
09/423,783	Von Seggern <i>et al.</i>	11/12/99
09/433,042	Barbas <i>et al.</i>	10/25/99
09/482,682	Von Seggern <i>et al.</i>	01/14/00
09/613,017	Nemerow <i>et al.</i>	07/10/00

<u>Int'l Appln. No.</u>	<u>Filing Date</u>
PCT/US00/00265	01/14/2000

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and make them of record in the file history of the above-captioned application.

\* \* \*

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:   
Stephanie L. Seidman  
Registration No. 33,779

**Dated: January 16, 2001**  
Attorney Docket 22908-1227B  
**Address all correspondence to:**  
HELLER EHRMAN WHITE & McAULIFFE LLP  
4250 Executive Square, 7th Floor  
La Jolla, California 92037  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
E-mail: sseidman@HEWM.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Barbas III et al.**  
Serial No.: 09/586,625  
Filed: June 2, 2000  
For: **LIGAND ACTIVATED TRANSCRIPTIONAL  
REGULATOR PROTEINS**  
Art Unit: 1645  
Examiner: Unassigned

**RECEIVED**

**JAN 22 2001**

TECH CENTER 1600/2900

RECEIVED  
TECH CENTER 1600/2900  
01 JAN 17 PM 2:55

**TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith is an Information Disclosure Statement, Forms PTO-1449 (7 pages), for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

( X )      The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

\* \* \*

Respectfully submitted,  
HELLER EHRMAN WHITE & McAULIFFE LLP

By:   
Stephanie L. Seidman  
Registration No. 33,779

**Dated: January 16, 2001**  
Attorney Docket 22908-1227B  
**Address all correspondence to:**  
HELLER EHRMAN WHITE & McAULIFFE LLP  
4250 Executive Square, 7th Floor  
La Jolla, California 92037  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
E-mail: sseidman@HEWM.com